Eliciting Potent & Safe Innate & Adaptive Immune Responses to Cancer with Bispecific Antibody Approaches to CD47 or CD28

Time: 4:45 pm
day: Day One

Details:

  • Bispecific antibodies (bsAbs) were developed to selectively target CD47 on tumor cells and regulate CD28-mediated T-cell co-stimulation, overcoming tolerability challenges encountered with monoclonal antibody (mAb) approaches while avoiding systemic toxicities associated with CD47 and CD28 targeting, respectively
  • CD47bsAbs with fully competent IgG1-Fc domains show potent anti-tumor activity in vitro and in vivo, prompting human trials due to favorable tolerability and PK profiles
  • The lead preclinical CD28-program, a PD-L1xCD28 bsAb, demonstrates anti-tumor efficacy and synergizes with TCEs in controlling tumor growth, showing promising PK and tolerability profiles for clinical translation

Speakers:

WALTER FERLIN
WALTER FERLIN